导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.99% | 3975/4773 |
| 近一周 | -3.20% | 3878/5462 |
| 近一月 | -3.27% | 1662/5421 |
| 近一季 | -2.06% | 1151/5209 |
| 近半年 | -5.48% | 2869/4920 |
| 近一年 | -16.38% | 3783/4366 |
| 近两年 | 24.83% | 2509/2954 |
| 近三年 | 6.01% | 1817/2253 |
| 成立以来 | -33.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.50% 4662/4961 |
8.64% 2570/5312 |
- - |
- - |
| 2025 | 3.34% 3129/4813 |
-6.80% 3400/3635 |
4.17% 841/4076 |
10.94% 3223/4524 |
-4.05% 3382/4813 |
| 2024 | 24.38% 290/3463 |
-4.75% 1760/2808 |
-8.24% 2196/3014 |
43.15% 18/3129 |
-0.58% 1468/3463 |
| 2023 | 3.70% 266/2656 |
3.92% 1089/2280 |
-2.80% 673/2385 |
7.32% 50/2515 |
-4.34% 968/2655 |
| 2022 | -24.64% 1238/2207 |
-17.64% 1233/1919 |
1.95% 1393/2016 |
-15.28% 1259/2113 |
5.93% 409/2208 |
| 2021 | -2.63% 864/1822 |
-14.38% 1174/1255 |
7.01% 707/1330 |
4.57% 336/1466 |
1.63% 854/1822 |
| 2020 | 21.91% 682/1250 |
-9.14% 657/1028 |
9.84% 781/1067 |
20.37% 56/1164 |
1.47% 1028/1184 |
| 2019 | 48.21% 115/1092 |
46.02% 23/754 |
-6.58% 511/804 |
-1.79% 678/850 |
10.62% 115/918 |
| 2018 | -25.34% 348/834 |
- - |
- - |
- - |
-3.31% 24/691 |
| 2017 | -9.65% 532/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.01% 369/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 鹏华券商A VS. 长安沪深300非周期A(740101) |